Dehydroepiandrosterone inhibits ADAMTS expression via an ERK-dependent mechanism in chondrocytes

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is characterized by cartilage degradation.
• Interleukin-1 beta (IL-1β) induces catabolic changes in chondrocytes.
• The ERK1/2 signaling pathway plays a role in OA pathogenesis.

Purpose of the Study:

• To investigate the anti-osteoarthritic effects of Dehydroepiandrosterone (DHEA).
• To elucidate the role of the ERK1/2 signaling pathway in DHEA's protective mechanism.
• To evaluate DHEA's impact on anabolic and catabolic gene expression in chondrocytes.

Main Methods:

• Rabbit chondrocytes were treated with IL-1β and DHEA.
• Gene expression of ADAMTS-4, ADAMTS-5, aggrecan, and collagen type 2 was analyzed using Polymerase Chain Reaction (PCR).
• ERK1/2 signaling pathway components were assessed via Western blotting.
• The ERK1/2 pathway was pharmacologically inhibited using PD98059.

Main Results:

• IL-1β induced ERK1/2 phosphorylation and upregulated catabolic genes (ADAMTS-4, ADAMTS-5) while downregulating anabolic genes (aggrecan, collagen type 2).
• DHEA administration reversed these IL-1β-induced changes, restoring gene expression balance.
• DHEA suppressed ERK1/2 phosphorylation, and its protective effects were enhanced by ERK1/2 pathway inhibition.

Conclusions:

• DHEA demonstrates protective effects against IL-1β-induced cartilage degradation in rabbit chondrocytes.
• DHEA's mechanism involves the suppression of ADAMTS enzymes in an ERK1/2-dependent manner.
• DHEA holds promise as a therapeutic agent for osteoarthritis.